

**FEE RULE**  
**FORM 13-502F1**  
**CLASS 1 REPORTING ISSUERS - PARTICIPATION FEE**

---

**Reporting Issuer Name:** IMMUNALL SCIENCE INC.

**Participation Fee for the Financial Year Ending:** December 31, 2010

Market value of listed or quoted securities:

Total number of securities of a class or series outstanding at the end of the issuer's most recent fiscal year 38,565,842

Simple average of the closing price of that class or series as of the last trading day of each of the month of the fiscal year (see clause 2.11(a)(ii)(A) or (B) of the Rule) \$0.015 (approx)

Market value of class or series \$  
(i) X (ii) \$578,487.63 (A)

(Repeat the above calculation for each class or series of securities of the reporting issuer that was listed or quoted on a marketplace in Canada or the United States of America at the end of the fiscal year) N/A (B)

Market value of other securities  
 ( See paragraph 2.11(b) of the Rule) N/A (C)  
 (Provide details of how value was determined.)

(Repeat for each class of securities) N/A (D)

**Capitalization**  
 (add market value of all classes and series of securities) (A) + (B) + (C) + (D) = \$578,487.63

**Participation Fee** \$700.00  
 (From Appendix A of the Rule, select the participation fee beside the capitalization calculated above.)

**New Reporting Issuer's Reduced participation fee**, if applicable  
 (see section 2.6 of the Rule)

Participation fee x Number of entire months remaining in the issuer's fiscal year \$  
 \_\_\_\_\_ =

Late Fee, if applicable \_\_\_\_\_  
 (As determined under section 2.5 of the Rule)